WaveRise Investments Limited

The unsuccessful Novartis India open offer highlights challenges in acquiring minority stakes, as Axis Capital reported zero shares tendered despite a ₹860.64 per share offer. The open offer, initiated to acquire a 26% stake from public shareholders as part of a broader agreement to obtain 70.68% control from Novartis AG, concluded without any public shareholders participating. While the Independent Directors Committee deemed the offer price fair, the lack of interest suggests limited appetite for selling at the offered valuation, potentially reflecting investor confidence in Novartis India's future prospects or a lack of perceived urgency to exit. This outcome may impact WaveRise Investments Limited and ChrysCapital's plans for integrating Novartis India, requiring alternative strategies to achieve full control.